OneVentures backs cancer biotech ImmVirX in $25 million Series B

You can read the full story here.

news-OneVentures-backs-cancer-biotech-ImmVirX-in-$25-million-Series-B

Join Our Mailing List

Our mission is to improve outcomes for patients with cancers in which immunotherapy treatments have limited effect

About Us
Our Technology
Immvirx logo
A clinical stage company developing novel oncolytic viruses to create powerful new cancer immunotherapy combinations
Twitter Linkedin
Company
© 2020 ImmVirX Pty Ltd • Site by Alex Shafren & Noise